Published
Warranty Issues of PDE-5 Inhibitors as Off-Label Use Action Mechanism based on Pharmacoeconomics for Patient Safety in Taxation System
Published in November 2022 Issue 11 (Vol. 9, Issue 11, 2022)

Abstract
Every government system follows the principle of ultimate powers in divided authorities responsible to promote public welfare and safety through constitutional practice of economic freedom. Pharmacoeconomics deals with cost-effective analysis in alignment with administrative functions of the government in relation to ethical behavior of private companies to comply with the rules and regulations expressed by the legislation and its comparative parliamentary legal system for guidance and control of appropriate ethical conduct as advocated by warranty issues of intellectual property. The intended design of PDE-5 inhibitors for marketing their products for public use as medication is indicated in their patent registration as strict compliance of advocating patient safety. Hence, ethical issues on product warranty of declared intended use, health risks for economic benefit, sexuality, and gender as socio-legal utilization of resources, empirical healthcare practice based on registered declared intellectual property of product design, and economic interventions in advocacy of constitutional monetary freedom are aimed to be discussed and resolved in this paper. Public funds are used by the government to advocate cost-effective analysis in pharmacoeconomics. Therefore, direct taxation of product services and practice of health promotion must be properly addressed and coordination in aligning the institutional goals with employment law for proper compliance of handling patented products. Furthermore, indirect taxation based on public funds must resolve issues concerning taxes collected from private companies handling patented drug products with clear specification of intended design for patient efficacy and safety. It is recommended to provide ways of promoting pharmacoeconomics without the conflict of suffering the declared intellectual property design for handling and misleading the acquired taxes for public funds, which in turn will also be compensated for unregistered intellectual property design based on patent law.
Authors (1)
ZHARAMA MONFERO LLARENA
Bournemouth UniversityBournemouth UniversityBournemouth UniversityBournemouth University
View all publications →Download Article
Best for printing and citation
File size: 0.0 MB
Format: PDF
Download Article
Best for printing and citation
File size: 0.0 MB
Format: PDF
Article Information
Published in:
November 2022 Issue 11 (Vol. 9, Issue 11, 2022)BJMHR0911002
BJMHR-09-000002
2022-11-01
Article Impact
Views:1,995
Downloads:2,167
scite_
Smart Citations
0Citing Publications
0Supporting
0Mentioning
0Contrasting
View Citations
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
How to Cite
MONFERO, Z., (2022). Warranty Issues of PDE-5 Inhibitors as Off-Label Use Action Mechanism based on Pharmacoeconomics for Patient Safety in Taxation System. British Journal of Medical and Health Research, 9(11), xx-xx. DOI:https://doi.org/10.5281/zenodo.7407720

